Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : How to EDIT your posts. -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (24)	11/15/1999 2:16:00 AM
From: RockyBalboa	Respond to of 36

Yes. Not much news, interesing situations around. Also I wanted to poke into SI's loopholes a bit. The HTML feature one poster raised really has a nice effect.

To: Mad2 who wrote (24)	11/15/1999 7:13:00 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 36

M, if you are in later, I'll do another demo. Just drop me a PM. Regards. C. Look at DITC STAC NMGC (thanks to M) MDLK SMRA CVCI ... -IDX on a spike. -RRRR on 2 spikes

To: Mad2 who wrote (24)	12/4/1999 11:46:00 AM
From: RockyBalboa	Read Replies (2) \| Respond to of 36

I see MDLK and NMGC look interesting from the chart. here is another one which could turn around, but it is not for short term, could take awhile CLTR (Coulter Pharmaceutical): -Insiders buying finance.yahoo.com biz.yahoo.com -news Saturday December 4, 10:45 am Eastern Time Coulter's lymphoma drug shows promising results NEW ORLEANS, Dec 4 (Reuters) - Bexxar, Coulter Pharmaceutical Inc.'s (NasdaqNM:CLTR - news) drug for treating lymphoma, showed promising results in Phase II studies when used in combination with conventional chemotherapy, according to a study on Saturday. The study by Cornell University showed that all patients with low grade non-Hodgkin's lymphoma went either into complete remission or saw partial response when on a regime of chemotherapy agent fludarabine followed by Bexxar. The Cornell study, funded by Coulter, said that following an initial five week treatment with only fludarabine, 14 percent of patients, or two out of 14, went into complete remission. ... biz.yahoo.com